AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
AbCellera (Nasdaq: ABCL) announced its participation in the Truist Securities AI Symposium on March 1, 2022, at 8:20 a.m. Pacific Time. The panel, titled “Integrated Platforms for AI-based Drug Discovery,” will feature executives from the Company discussing groundbreaking advancements in drug development. Interested parties can access a live audio webcast through AbCellera's Investor Relations website, with a replay available afterwards. AbCellera specializes in antibody discovery, partnering with various drug developers to expedite the development process for new treatments.
- None.
- None.
A live audio webcast of the panel may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223006146/en/
Inquiries
Media:
Business Development:
Investor Relations:
Source:
FAQ
When will AbCellera's panel at the Truist Securities AI Symposium take place?
What is the focus of AbCellera's panel at the symposium?
How can I access the live webcast of AbCellera's symposium panel?
What is AbCellera's primary focus as a company?